Tag: stage

Investment supports the development of first-in-class, non-addictive, non-hallucinogenic molecules with a non-synaptic target, differentiated from existing drugs

Strasbourg, France and Charleroi, Belgium, June 11^th  2025 – Elkedonia SAS, a company pioneering a novel neuroplastogen approach to develop therapeutic agents to treat depression and other neuropsychiatric condition, announced today that it has closed an oversubscribed EUR 11.25 million Seed funding round. The round was co-led by Kurma Partners, WE Life Sciences and the French Tech Seed fund managed on behalf of the French government by Bpifrance as part of France 2030, with participation from Argobio, Angelini Ventures, CARMA Fund, Capital Grand Est and Sambrinvest. Elkedonia is bringing together stakeholders from across the European ecosystem, with headquarters in Strasbourg, France and an affiliate in Charleroi, Belgium.

Strasbourg, France, et Charleroi, Belgique, 11 juin 2025 - Elkedonia SAS, société pionnière dans le développement de neuroplastogènes thérapeutiques destinés à traiter la dépression et d'autres maladies neuropsychiatriques, a annoncé aujourd'hui un tour de financement d’amorçage de 11,25 millions d'euros. Ce tour de table a été co-dirigé par Kurma Partners, WE Life Sciences et le fonds French Tech Seed géré pour le compte du gouvernement français par Bpifrance dans le cadre de France 2030, avec la participation d'Argobio, Angelini Ventures, CARMA Fund, Capital Grand Est et Sambrinvest. Elkedonia rassemble plusieurs acteurs de l'écosystème européen, avec un siège à Strasbourg, en France, et une filiale à Charleroi, en Belgique.

London, UK, 11 June 2025 - Persica Pharmaceuticals Limited (Persica), a clinical stage biotechnology company developing a transformative treatment for chronic Low Back Pain (cLBP), today announces that it has been granted a patent by the European Patent Office for PP353, its clinical stage asset.

EDMONTON, Alberta, June 10, 2025 (GLOBE NEWSWIRE) -- Quest PharmaTech Inc. (TSX-V: QPT) (“Quest” or the “Company”), a Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies, announced today that Quest was not informed or consulted, opposes and will not support the recently announced acquisition by privately held South Korea-based OQPBIOM Inc. (“OQM”) of a controlling interest in AdBioTech Co., Ltd. (“AdBioTech”), a public company listed on KOSDAQ in South Korea. OQM has announced that AdBioTech is the corporate vehicle through which it wishes to pursue the funding and advancement of its immunotherapy assets.

June 11, 2025, 12:01 AM CET